A grounded synthesis of representative open-access studies on amitraz Varroa control. Every claim is traceable to a cited study.
⚠️ Not label instructions. Amitraz product registration, strip dose and treatment duration vary by country, and unregistered "amitraz EC" use is off-label. Figures below are study-reported. Follow your product label. See the decision framework.
🔍 Search these papers · 📂 Browse the Varroa corpus
Amitraz is a formamidine acaricide, delivered to colonies mainly as plastic contact strips (the registered product Apivar). It works as an agonist at the mite's β-octopamine receptor (Octβ2R); its selective toxicity — lethal to mites, relatively gentle to bees — arises because the honey-bee version of this receptor is less sensitive to amitraz and its active metabolite than the mite's (Guo 2021). As a contact acaricide it reaches phoretic mites only, so like the other strips it works best when little brood shields the mite population.
For two decades amitraz has been the most reliable synthetic option and the commercial mainstay. Modelling of Apivar treatment shows that treatment in the absence of brood is optimal, and that with a long broodless winter window an efficacy near 98.8% is needed to hold the mite population stable year to year — attainable for amitraz where mites remain susceptible (Almecija 2022). The model also delivers the central warning: resistance can cause treatment failure even when a beekeeper keeps the initial infestation low (Almecija 2022). For rapid knock-down of a damaging autumn infestation, a registered combination of amitraz (Apivar) with thymol (Apiguard) controlled mites nearly as fast as the off-label, unregistered "amitraz EC" that some beekeepers reach for (Aurell 2024).
Amitraz held up far longer than the pyrethroids and coumaphos, but its decline is the defining contemporary issue. In-vitro bioassays and Apivar field tests across US commercial operations found a wide range of amitraz resistance, from none to outright control failure, with resistance ratios correlating with reduced field efficacy (Rinkevich 2020). The molecular basis is now being pinned down — and it is more than one mutation in the Octβ2R receptor:
French data describe resistance occurring in patchy "islands," generally milder than the near-total resistance seen with pyrethroids or coumaphos, and not explained by any single nucleotide polymorphism (Marsky 2024). There is a hopeful wrinkle: in a monitored apiary, resistance partially declined after amitraz was withdrawn, though it did not return to full susceptibility (Poirot 2026) — evidence that rotating away from amitraz can relieve selection pressure.
Amitraz breaks down into metabolites (2,4-DMA and DMPF) that contaminate honey stored in the combs, exceeding the maximum residue limit in about 10% of samples in one fumigation trial (Pohorecka 2018) — a reason to keep treatment off honey supers and outside flows. At sublethal levels amitraz and its metabolite also modulate honey-bee physiology, including cardiac function (O'Neal 2017). Resistance can be both target-site and metabolic, the latter via elevated detoxification activity (Kamler 2016).
Because exclusive reliance is exactly what drives resistance, the literature is unanimous on the response: monitor amitraz efficacy after every treatment, rotate to a different mode of action (organic acids, thymol), and use early-season resistance genotyping where available to predict late-season failure before it costs colonies (Rinkevich 2020; Rinkevich 2023). Lab resistance testing itself is temperature-sensitive and needs standard conditions to be comparable (Rinkevich 2024).
Amitraz is still the most effective synthetic strip and, where mites remain susceptible, the strongest single product available — but it is no longer something to lean on alone. Treat over minimal brood, verify it worked, keep it off honey, and rotate it through a programme that includes organic acids and biotechnical methods so resistance never gets entrenched.
Rinkevich, PLoS ONE 2020 · 97 citations — Documents bona fide amitraz control failures in US operations; resistance correlates with reduced Apivar efficacy.
Guo et al., eLife 2021 · 53 citations — Identifies Octβ2R as amitraz's target and explains why bees tolerate it but mites do not.
Rinkevich, Pest Management Science 2023 · 17 citations — A receptor mutation enabling genotyping-based resistance surveillance in the US.
Marsky et al., Insects 2024 · 12 citations — Resistance as patchy "islands," milder than pyrethroid/coumaphos resistance.
Almecija et al., Pest Management Science 2022 · 5 citations — Broodless treatment optimal; resistance drives failure even at low initial infestation.
Pohorecka et al., Journal of Veterinary Research 2018 · 9 citations — Amitraz metabolites contaminate comb honey, exceeding the MRL in 10% of samples.
Curated synthesis — not exhaustive, and not a substitute for the product label. Related: Decision framework · Synthetic pyrethroids & coumaphos · Acaricides & resistance · Oxalic acid · Treatment calendar.